Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio
SAN DIEGO, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Resmed ( NYSE: RMD, ASX: RMD ) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company also announced that board member Rich Sulpizio is thanked for two decades of contributions to Resmed, ...
Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio - ResMed ( NYSE:RMD )
Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics Operations Her appointment brings over 30 years of strategic, commercial, and operational expertise in the pharmaceutical and broader healthcare industry, with a focus on digital innovation
Here is What to Know Beyond Why AbbVie Inc. ( ABBV ) is a Trending Stock
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
If You'd Invested $1,000 in AbbVie Stock 10 Years Ago, Here's How Much You'd Have Today
You'd be sitting pretty right now.
This Red-Hot Vanguard ETF Just Hit an All-Time High. Here's Why It's Still Worth Buying in August.
The Vanguard Dividend Appreciation ETF has an excellent balance of growth, income, and value stocks.
Marjorie Taylor Greene Keeps Buying UnitedHealth Stock Along With Fellow Investors Buffett And Burry - UnitedHealth Group ( NYSE:UNH )
Marjorie Taylor Greene recently bought UnitedHealth shares. The purchase came before investors Warren Buffett and Michael Burry revealed new stakes in the company. Get more market-moving news first with AI-powered analysis that turns noise into opportunity.
Here's How Much $100 Invested In AbbVie 5 Years Ago Would Be Worth Today - AbbVie ( NYSE:ABBV )
AbbVie ABBV has outperformed the market over the past 5 years by 2.74% on an annualized basis producing an average annual return of 16.46%. Currently, AbbVie has a market capitalization of $362.01 billion.
3 Dividend Stocks to Double Up On Right Now
These stocks offer great dividends and more.
Xilio Revenue Jumps 246 Percent in Q2
Xilio Therapeutics ( NASDAQ:XLO ) , a clinical-stage biotechnology company developing tumor-activated immuno-oncology therapies, reported its Q2 2025 results on August 14, 2025. The company reported collaboration and license revenue ( GAAP ) of $8.1 million, up sharply from $2.4 million ( GAAP ) ...
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors
NEW YORK, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 ...
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025.
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
REYKJAVIK, Iceland, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and ...
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
REYKJAVIK, Iceland, August 13, 2025 - Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and provided a summary of ...
PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last?
Pfizer's new and acquired drugs record sales of $4.7B in H1 as COVID-products related volatility eases.
Healthy Returns: FDA launches program to streamline creation of new U.S. drug manufacturing sites
A new FDA program will use a two-phase approach to help boost domestic drug manufacturing, while OpenAI is leaning into health care with the launch of GPT-5.
The Zacks Analyst Blog Highlights Pfizer, Novo Nordisk and Eli Lilly
Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.
MindMed ( MNMD ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, July 31, 2025, at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
Should Pfizer Stock Be in Your Portfolio After Solid Q2 Results?
Pfizer posts strong Q2 earnings and raises EPS outlook, with oncology growth and new drugs offsetting looming headwinds.
My 3 Favorite Stocks to Buy Right Now
These tried-and-true businesses are performing well against a volatile backdrop.
2 Dividend ETFs to Buy With $1,000 and Hold Forever
Investing in quality dividend ETFs can offer a great way to boost your portfolio returns.
2 High-Yielding ETFs That You Can Rely on for Recurring Income
The funds listed here offer a good mix of safety, diversification, and dividends.
3 Stocks Retirees Should Absolutely Love
These stocks check off all the boxes for investors no longer receiving a paycheck.
AbbVie Inclusion In Medicare Drug Talks Doesn't Justify Lawsuit: Court - AbbVie ( NYSE:ABBV )
A federal judge dismissed a lawsuit filed by four chambers challenging Medicare drug pricing powers. AbbVie's Imbruvica was among the drugs targeted, but the court found no legal standing to sue. The next 100%+ earnings move could hit this month. See how to find it live on Wednesday → AbbVie ...
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% - Genmab ( NASDAQ:GMAB )
Epcoritamab combo reduced the risk of disease progression or death by 79% in the Phase 3 FL trial. Genmab raised its 2025 revenue outlook to $3.5-$3.7 billion after Q2 beat and 19% Y/Y growth. This simple system has nailed 1,000+ post-earnings winners. Get in before Q3 trades take off →
IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates
Ironwood shares jump 9.3% as second-quarter earnings and revenues top estimates. The company maintains its 2025 outlook.
Genmab Announces Financial Results for the First Half of 2025
August 7, 2025 Copenhagen, Denmark. Interim Report for the First Half Ended June ...
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory ( R/R ) Follicular Lymphoma ( FL )
Company Announcement ...
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory ( R/R ) Follicular Lymphoma ( FL )
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) ...
Ironwood ( IRWD ) Q2 EPS Jumps 600%
Ironwood Pharmaceuticals ( NASDAQ:IRWD ) , a specialty pharmaceutical company known for developing therapies for gastrointestinal conditions, delivered financial results on August 7, 2025, for its second quarter. The company beat analyst expectations on both non-GAAP earnings and GAAP revenue.
Global Medical Aesthetic Devices Market to Reach $37.9 Billion by 2029
Boston, Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- As global demand for aesthetic enhancement rises, medical aesthetic devices are transforming how patients approach cosmetic care.
Trump Threatens Pharma With Potential 250% Tariffs In 18 Months: 'We Want Pharmaceuticals Made In Our Country' - AbbVie ( NYSE:ABBV ) , Amgen ( NASDAQ:AMGN )
President Donald Trump has indicated the possibility of imposing tariffs on imported pharmaceuticals that could rise up to 250%, indicating the highest rate he has proposed so far.
AbbVie Inc. ( ABBV ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
AbbVie ( ABBV ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, July 31, 2025 at 1:00 p.m. ETChief Financial Officer - Rob MichaelContinue reading ...
AbbVie Raises 2025 Outlook After Q2 Beat
AbbVie ( NYSE:ABBV ) reported second quarter 2025 results on July 31, 2025, delivering adjusted EPS of $2.97 ( up $0.11 from guidance midpoint ) and net revenues of $15.4 billion ( up $400 million from expectations ) . Management raised full-year revenue guidance by $800 million, to $60.5 ...
J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
JNJ lifts 2025 sales and EPS outlook on strong Q2 results, with new drug launches and MedTech gains fueling momentum.
How Did Skyrizi and Rinvoq Sales Contribute to AbbVie's Q2 Results?
AbbVie's Q2 results show Skyrizi and Rinvoq powering growth, offsetting Humira declines and lifting 2025 sales outlook.
If You'd Invested $1,000 in AbbVie ( ABBV ) Stock 10 Years Ago, Here's How Much You'd Have Today
Spoiler: You would have done well -- and even better if you'd reinvested your dividends.
3 Unstoppable Stocks to Buy in August
Here are hot stocks to buy in a hot month.
3 Dividend Champion Stocks I'm Watching in 2025
Other investors might want to watch these high-yield dividend stocks, too.
Why AbbVie Stock Flew Higher on Friday
A solid quarterly earnings report reverberated though the pundit community that day.
Why Is AbbVie Stock Gaining Friday? - AbbVie ( NYSE:ABBV )
Q2 sales rose 6.6% to $15.42 billion, beating estimates; EPS of $2.97 missed the $3.23 consensus. FY25 adjusted EPS guidance raised to $11.88-$12.08 vs estimate of $12.24. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily. On Thursday, AbbVie Inc.
Deal Dispatch: MEG Bidding War Heats Up, L Catterton Takes Bite Out Of Kisshokichi, Sunnova's Still Shining - Baker Hughes ( NASDAQ:BKR ) , AbbVie ( NYSE:ABBV )
Dye & Durham launches review, dodges proxy battle with Plantro. Hellman & Friedman is looking to sell energy data platform Enverus to Blackstone. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
5 Dividend Stocks With Solid Returns And More Growth Ahead - Broadcom ( NASDAQ:AVGO ) , AbbVie ( NYSE:ABBV )
By design, dividend stocks are committed to regular income. But that doesn't mean they can't generate robust returns. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings
PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar.
3 Dividend Healthcare Stocks to Buy Hand Over Fist Before They Double
These pharmaceutical giants are well worth a second look.
Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...' - AbbVie ( NYSE:ABBV ) , Amgen ( NASDAQ:AMGN )
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences. ArrivedBuy shares of homes and vacation rentals for as little as $100. Get Started
Why AbbVie Stock Slumped Today
An encouraging quarterly earnings report was dampened by a new demand from President Trump.
AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View
ABBV tops Q2 forecasts and lifts 2025 EPS outlook as Rinvoq and Skyrizi drive growth amid Humira's decline.
Why Is AbbVie Stock Gaining On Thursday? - AbbVie ( NYSE:ABBV )
AbbVie Q2 sales hit $15.42 billion vs. $14.98 billion estimate, driven by strong Skyrizi and Rinvoq performance. EPS rose 12% Y/Y to $2.97, missing $3.23 estimate; AbbVie raised its 2025 earnings outlook to $11.88-$12.08. Get special access to three exclusive "Top 10 Stocks" power lists today, ...
